DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF CTLA4IG IN PATIENTS WITH PSORIASIS

这项II期研究是一项多中心、随机、安慰剂对照研究。 旨在评估安全性、药代动力学、药效学 BMS-188667（CTLA 4 Ig）在患者中的免疫原性和生物活性 寻常型银屑病 存活的患者将有稳定的斑块 银屑病持续时间超过6个月，并且至少累及 10%体表面积（BSA），并且至少有一项标准不合格 抗银屑病治疗的毒性和/或无效性。 信息从 本研究将用于开发阶段的给药方案 在该患者人群中进行的III项研究。

This Phase II study is a multi-center, randomized, placebo-controlled trial designed to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and biologic activity of BMS-188667 (CTLA4Ig) in patients with psoriasis vulgaris. Eligable patients will have stable plaque psoriasis of greater than six months duration, and involvement of at least 10% body surface area (BSA), and will have failed at least one standard anti-psoriatic therapy for toxicity and/or inefficacy. Information from this study will be used in the development of dosing schedules in Phase III studies in this patient population.